Experience with anti-HER2 therapies in bladder cancer to date: Motivated by the success of anti-HER2 approaches in other carcinomas (breast, stomach), several clinical trials were conducted in urothelial carcinoma. Here, ERBB2 is linked to urothelial carcinoma.